Capital Markets Event: View a recording and access materials presented at OXB’s Capital Markets Event held on 2nd June 2026.

VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category.

Cancer Research Horizons: On the Horizons

Location: Europe Where: London, UK Start Date: 11th Jun, 2026

Join Kyriacos Mitrophanous, Chief Innovation Officer at OXB, at the Cancer Research Horizons On the Horizon Breakfast Event on 11 June at The Royal Society, where he will join leading researchers, biotech founders, and investors to discuss one of the most rapidly advancing areas in cell and gene therapy: in vivo CAR-T.

In vivo CAR-T has the potential to transform treatment development by removing the need for complex ex vivo manufacturing and enabling scalable, off-the-shelf therapies for cancer and autoimmune diseases.

As clinical momentum builds, investment increases, and major strategic deals continue to shape the landscape, in vivo CAR-T is emerging as one of the most heavily funded and closely watched areas in oncology.

During this discussion, attendees will gain insights into:

  • The latest scientific and clinical developments driving the field forwardWhy investors and industry leaders are increasingly focused on in vivo CAR-T
  • Opportunities and challenges for translating innovation into patient impact
  • OXB’s CDMO perspective on supporting the next generation of cell therapies

Join us for an engaging conversation with experts from across the biotech ecosystem and discover what lies ahead for this exciting and evolving field.

Date: 11 June
Venue: The Royal Society
Event: Cancer Research Horizons – On the Horizon Breakfast Event

Register your interest